Close

Allergan (AGN) August weekly volatility flat into Q2 and outlook

Go back to Allergan (AGN) August weekly volatility flat into Q2 and outlook

Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q

August 9, 2016 9:08 AM EDT

Piper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.

Analyst David Amsellem commented, "Allergan... More